Aster Capital Management DIFC Ltd Sells 4,949 Shares of DaVita Inc. (NYSE:DVA)

Aster Capital Management DIFC Ltd cut its stake in DaVita Inc. (NYSE:DVA - Free Report) by 92.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 394 shares of the company's stock after selling 4,949 shares during the quarter. Aster Capital Management DIFC Ltd's holdings in DaVita were worth $59,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. MML Investors Services LLC lifted its holdings in shares of DaVita by 1.3% during the 3rd quarter. MML Investors Services LLC now owns 5,300 shares of the company's stock valued at $869,000 after purchasing an additional 68 shares in the last quarter. Exchange Traded Concepts LLC lifted its position in DaVita by 8.3% in the 4th quarter. Exchange Traded Concepts LLC now owns 891 shares of the company's stock valued at $133,000 after acquiring an additional 68 shares in the last quarter. Impact Partnership Wealth LLC increased its holdings in DaVita by 3.7% during the 4th quarter. Impact Partnership Wealth LLC now owns 1,941 shares of the company's stock worth $290,000 after purchasing an additional 70 shares in the last quarter. Contravisory Investment Management Inc. raised its stake in shares of DaVita by 1.2% in the 4th quarter. Contravisory Investment Management Inc. now owns 6,082 shares of the company's stock valued at $910,000 after purchasing an additional 73 shares during the period. Finally, Nilsine Partners LLC boosted its position in shares of DaVita by 0.8% during the fourth quarter. Nilsine Partners LLC now owns 11,160 shares of the company's stock worth $1,669,000 after buying an additional 92 shares during the period. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently commented on DVA shares. Cowen reissued a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. Barclays increased their price objective on shares of DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Tuesday, February 18th. StockNews.com upgraded DaVita from a "hold" rating to a "buy" rating in a report on Thursday, April 10th. Finally, Sanford C. Bernstein set a $184.00 price objective on DaVita in a research note on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, DaVita has an average rating of "Hold" and an average price target of $166.33.

DaVita Stock Performance

DVA stock traded down $2.91 during midday trading on Tuesday, reaching $147.98. 247,871 shares of the company were exchanged, compared to its average volume of 823,178. DaVita Inc. has a one year low of $125.64 and a one year high of $179.60. The firm has a market capitalization of $11.84 billion, a price-to-earnings ratio of 13.79, a price-to-earnings-growth ratio of 1.07 and a beta of 1.04. The business has a 50-day moving average price of $151.61 and a two-hundred day moving average price of $156.51. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Equities research analysts forecast that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.